Perspective Therapeutics, Inc.

AMEX:CATX

Medical - Devices

Healthcare
$0.78 +0.50%

+$0.02 today

Market cap
$94.67M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$107.27
52W Low $1.96High $6.16

Volume 1.84M

Average 1.44M

Returns on capital

Perspective Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-49.8%

avg -49.3%

ROIC

-47.0%

avg -41.7%

ROA

-38.6%

avg -38.3%

Analysis

ROA is currently the strongest return metric at -38.6% versus its period average of -38.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Johan Spoor

Chief Executive Officer & DirectorUSD 1.1M54——

Markus Puhlmann

Chief Medical OfficerUSD 737.4K60178.54K0.23%

Jonathan R. Hunt

Chief Accounting OfficerUSD 611.17K59——

Joel David Sendek

CFO & Principal Financial OfficerUSD 574.29K59——

Michael K. Schultz

Co-Founder & Senior Scientific Advisor————

Paul Lyne

Chief Science Officer————

Andrew Bright

Executive Vice President of Brachytherapy————

Chris Nenno

General Counsel & Corporate Secretary————

Shane Cobb

Executive Vice President of Operations————

Annie J. Cheng

Vice President of Investor Relations—50——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 12, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

3

$72,487.60

Sells

7

$1.62M

Net Transaction Value

−$1.55M

Net selling

Most Active

Lantheus Alpha Therapy, LLC

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 12, 26

Puhlmann Markus

Direct

Buy$29.6K
Nov 11, 26

Puhlmann Markus

Direct

Buy$5K
Nov 11, 26

Spoor Johan M.

Direct

Buy$37.9K
Sep 4, 26

Lantheus Alpha Therapy, LLC

Direct

Sell$526.1K
Sep 3, 26

Lantheus Alpha Therapy, LLC

Direct

Sell$250.9K
Sep 2, 26

Lantheus Alpha Therapy, LLC

Direct

Sell$131.2K
Sep 1, 26

Lantheus Alpha Therapy, LLC

Direct

Sell$111.6K
Sep 1, 26

Lantheus Holdings, Inc.

Direct

Sell$111.6K
Aug 31, 26

Lantheus Holdings, Inc.

Direct

Sell$245.6K
Aug 31, 26

Lantheus Alpha Therapy, LLC

Direct

Sell$245.6K

Summary

Insiders reported 3 buys worth $72,487.60 and 7 sells worth $1.62M over the last 12 months. That adds up to net selling of $1.55M. Lantheus Alpha Therapy, LLC was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A-50.1%
+140.8% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at -50.1% over three years. Forward estimates point to Revenue at +140.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Perspective Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CATX's management, answered from reported figures.

Who manages CATX?

Perspective Therapeutics, Inc. (CATX) lists 10 active executives. The top listed executive is Markus Puhlmann, Chief Medical Officer.

Are CATX insiders buying or selling?

Recent insider activity shows net buying of $79.65M.